[1] |
Schwartz RA, Fernández G, Kotulska K, et al. Tuberous sclerosis complex: advances in diagnosis, genetics, and management[J]. J Am Acad Dermatol, 2007, 57(2): 189⁃202. DOI: 10.1016/j.jaad. 2007.05.004.
|
[2] |
Tu J, Foster RS, Bint LJ, et al. Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions[J]. Australas J Dermatol, 2014, 55(1): 63⁃69. DOI: 10.1111/ajd.12125.
|
[3] |
Vasani RJ. Facial angiofibromas of tuberous sclerosis treated with topical sirolimus in an Indian patient[J]. Indian J Dermatol, 2015, 60(2): 165⁃169. DOI: 10.4103/0019⁃5154.152516.
|
[4] |
Northrup H, Krueger DA, Group ITSCC. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference[J]. Pediatr Neurol, 2013, 49(4): 243⁃254. DOI: 10.1016/j.pediatrneurol.2013.08.001.
|
[5] |
Nathan N, Wang J, Li S, et al. Improvement of tuberous sclerosis complex (TSC) skin tumors during long⁃term treatment with oral sirolimus[J]. J Am Acad Dermatol, 2015, 73(5): 802⁃808. DOI: 10.1016/j.jaad.2015.07.018.
|
[6] |
Salido⁃Vallejo R, Ruano J, Garnacho⁃Saucedo G, et al. Facial angiofibroma severity index (FASI): reliability assessment of a new tool developed to measure severity and responsiveness to therapy in tuberous sclerosis⁃associated facial angiofibroma[J]. Clin Exp Dermatol, 2014, 39(8): 888⁃893. DOI: 10.1111/ced. 12398.
|
[7] |
Koenig MK, Hebert AA, Roberson J, et al. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex[J]. Drugs R D, 2012, 12(3): 121⁃126. DOI: 10.2165/11634580⁃000000000⁃00000.
|
[8] |
Sampson JR. Therapeutic targeting of mTOR in tuberous sclerosis[J]. Biochem Soc Trans, 2009, 37(Pt 1): 259⁃264. DOI: 10.1042/BST0370259.
|
[9] |
Li S, Takeuchi F, Wang JA, et al. Mesenchymal⁃epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas[J]. Proc Natl Acad Sci USA, 2008, 105(9): 3539⁃3544. DOI: 10.1073/pnas.0712397105.
|
[10] |
Darling TN. Hamartomas and tubers from defects in hamartin⁃tuberin[J]. J Am Acad Dermatol, 2004, 51(1 Suppl): S9⁃11. DOI: 10.1016/j.jaad.2004.01.009.
|
[11] |
Paghdal KV, Schwartz RA. Sirolimus (rapamycin): from the soil of Easter Island to a bright future[J]. J Am Acad Dermatol, 2007, 57(6): 1046⁃1050. DOI: 10.1016/j.jaad.2007.05.021.
|
[12] |
Hofbauer GF, Marcollo⁃Pini A, Corsenca A, et al. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis[J]. Br J Dermatol, 2008, 159(2): 473⁃475. DOI: 10.1111/j.1365⁃2133.2008.08677.x.
|
[13] |
Del Bufalo D, Ciuffreda L, Trisciuoglio D, et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus[J]. Cancer Res, 2006, 66(11): 5549⁃5554. DOI: 10.1158/0008⁃5472.CAN⁃05⁃2825.
|
[14] |
Tanaka M, Wataya⁃Kaneda M, Nakamura A, et al. First left⁃right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex[J]. Br J Dermatol, 2013, 169(6): 1314⁃1318. DOI: 10.1111/bjd.12567.
|
[15] |
Salido R, Garnacho⁃Saucedo G, Cuevas⁃Asencio I, et al. Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis⁃associated facial angiofibroma[J]. J Eur Acad Dermatol Venereol, 2012, 26(10): 1315⁃1318. DOI: 10.1111/j.1468⁃3083.2011.04212.x.
|
[16] |
Fogel AL, Hill S, Teng JM. Advances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in dermatology[J]. J Am Acad Dermatol, 2015, 72(5): 879⁃889. DOI: 10.1016/j.jaad.2015.01.014.
|